Status:
COMPLETED
VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness
Lead Sponsor:
Viveve Inc.
Conditions:
Vaginal Laxity Following Childbirth
Sexual Function Following Childbirth
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Outside United States (OUS) Post-Market Parallel Group Exploratory Study Design The objective of this study is to determine the safety and effectiveness of the Viveve System to treat the vaginal intr...
Detailed Description
A prospective, longitudinal, randomized, single-blind, sham controlled clinical study is planned. This study is designed to demonstrate that the active treatment (i.e., Viveve Procedure) is superior t...
Eligibility Criteria
Inclusion
- Key
- Able to understand and voluntarily sign the informed consent form
- Pre-menopausal and ≥ 18 years of age
- At least one full term vaginal delivery (\> 37 completed weeks gestation) at least 12 months prior to enrollment date
- Experiences vaginal looseness (laxity) during vaginal intercourse
- Subject must have a screening blood count and metabolic panel including FSH level of \<35 mIU/mL (35 IU/L).
- Subject must have a normal pelvic exam at baseline and negative chlamydia and gonorrhea cultures during the screening period.
- Subject had a normal PAP within last three years, cytology, no HPV and within last five years, cytology and no HPV.
- Subject must be willing to engage in vaginal intercourse at least once per month.
- Subject must be in a monogamous, heterosexual relationship for at least six months prior to screening visit with a partner who is sexually functional and available at least 50% of the time.
- Subject is surgically sterilized, or is willing to use an acceptable method of birth control that was begun at least 3 month prior to screening and to be continued or throughout the duration of the study \[i.e., barrier method (e.g., diaphragm), hormonal therapy (subcutaneous, injectable, or oral contraceptive) intrauterine device\], or partner is surgically sterilized
- Key
Exclusion
- Pregnant or planning to become pregnant within the next 12 months or has had a delivery within the last 12 months.
- Currently breastfeeding or discontinued breast feeding fewer than 6 months prior to enrollment
- History of a genital fistula, a thin recto-vaginal septum as determined by the investigator, or history of a fourth degree laceration during screening physical exam
- Clinically significant pelvic organ prolapse
- Currently meets the criteria for a female sexual disorder, including DSM V, FSAD, FOD, Genitopelvic Pain, Sexual Aversion, Dyspareunia, or Vaginismus, and has not been treated for this condition within the past 12 months
- Beck Depression Inventory score \> 14
- DSM-5 psychiatric diagnosis exhibiting clinically significant symptoms
- Taking SSNRI or SSRI drugs
- Not willing to abstain from vaginal intercourse or use of tampons until 10-day follow-up visit completed
- Evidence of active sexually transmitted disease upon vaginal exam that precludes treatment
- History of genital herpes
- Clinically significant abnormalities in clinical chemistry or hematology at the time of screening
- Currently taking prescribed medications, OTC products or supplements that may impact or enhance sexual function (e.g., antihypertensive, psychotropic, chemotherapeutic agent, PD5 Inhibitors) as assessed by the investigator
- Currently undergoing chemotherapy, radiation therapy, or pelvic floor physical therapy
- Has an implantable pacemaker, an automatic implantable cardioverter/defibrillator (AICD), or any other implantable electrical device, as these devices may be adversely affected by radiofrequency fields or current
- Has undergone the Viveve Procedure previously
- Has medical condition that in investigator's opinion may interfere with wound healing response
- Has an acute or a chronic vaginal or vulvar disorder (e.g., vaginal atrophy, pain including vulvodynia, vulvar vestibulitis dysethetic vulvodynia or vulvar dystrophy, current/chronic papulosquamous vulvar dermatoses (e.g., psoriasis lichen planus, tinea cruris, lichen sclerosis, seborrhea dermatitis, contact or irritant dermatitis, lichen simplex, eczema) or bullous dermatoses or systemic diseases with potential involvement of vulva)
- Has Irritable Bowel Syndrome or Crohn's Disease
- Has dyspareunia defined as recurrent or persistent painful intercourse that affects sexual activity
- Has been in another clinical study within four weeks of screening, or is not willing to abstain from enrolling in other clinical studies for duration of trial
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT02261974
Start Date
January 1 2015
End Date
April 1 2016
Last Update
August 28 2018
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Allan Centre
Calgary, Alberta, Canada, AB T2 7G9
2
Complexe Medical St-Laurent
Montreal, Quebec, Canada, H4R 0B7
3
Les Cours Medical Centre
Montreal, Quebec, Canada, QC H3 A1 T5
4
Exogenia Institute of Anti-Aging and Regenerative Medicine
Sherbrooke, Canada